ALK Abello's EURneffy® Nasal Spray Outperforms Auto-Injectors in…

Event summary

ALK Abello presented data at BSACI 2026 showing EURneffy® nasal adrenaline spray was rated significantly less burdensome than adrenaline auto-injectors (AAIs) in a UK study involving 90 participants.
In a Canadian study, EURneffy® was rated easier to use than AAIs across all nine measures assessed, with 94% of participants finding it more intuitive.
The studies highlighted that fear, stress, and the physical bulk of AAIs are significant barriers to consistent use.
EURneffy® was described as calming to use, comforting to carry, and offered greater independence and discretion, particularly for teenagers and young adults.
The findings were presented by Dr Pamela Ewan and Dr Shelley Dua at the BSACI Conference in Newport, Wales, on October 12, 2026.

The big picture

The data presented at BSACI 2026 underscores a growing trend in the allergy treatment sector towards more patient-friendly, needle-free solutions. ALK Abello's EURneffy® nasal spray is positioned to capitalize on this shift, potentially disrupting the dominance of traditional adrenaline auto-injectors. The findings also highlight the importance of addressing emotional and practical barriers to ensure consistent use of emergency anaphylaxis treatments.

What we're watching

Market Adoption: How ALK Abello will leverage these findings to accelerate the adoption of EURneffy® among patients and healthcare providers.
Regulatory Approvals: Whether the positive patient preference data will facilitate faster regulatory approvals in additional markets.
Competitive Positioning: The pace at which ALK Abello can differentiate EURneffy® from existing AAI products in the competitive anaphylaxis treatment market.